Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

Readers’ letters on the march of electronic payments, choice in super withdrawals, government spending, high energy costs, ...

Capping indirect funding will decimate biomedical research, which has been the engine of the U.S. economy and the envy of the ...

You may also consider locations – especially corporate-owned pharmacies – that also offer urgent care or primary care ...

We urge President Donald Trump to reconsider his recent rescission of a Biden administration measure designed to lower ...

Just days after pointed, but civil, debate on a proposal to expand efforts to control prescription drug costs, the House ...

The FDA has announced that the shortage of Wegovy and Ozempic, medications used for weight loss and diabetes management, is ...

Yosemite Drug in the Coarsegold Historic Village, whose clients are generally 60 or older, announced it will close up shop ...

The Federal Trade Commission (FTC) and Department of Justice (DOJ) are supposed to prevent monopolistic behavior, but their ...

Esperion Therapeutics has two approved LDL-C lowering therapies, Nexletol and Nexlizet, but lacks a strong pipeline for future growth.

Ozempic and Wegovy, the popular GLP-1 drugs for diabetes and weight loss, are no longer in short supply, the FDA declared ...

Debate over whether or not the Affordable Care Act, commonly known as Obamacare, worked and how President Trump's executive ...